Tip 112: RSV immunisation

Synergis (Palivizimab) is a humanized monoclonal antibody and provides passive immunity against RSV. It reduces hospitalization rates and serious complications amongst high risk children. These are:

–       Less than 35 weeks gestation and under 6 months old at onset of RSV season

–       Under 2 years old on treatment for chronic lung disease

–       Under 2 years old with haemodynamically significant heart disease

Reference: Immunisation against infectious diseases (The Green Book) Department of Health, March 2014

This entry was posted in Prematurity, Respiratory. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s